Target | Drug name | Drug class | Dosage and route | Evidence | Key references |
---|---|---|---|---|---|
TNFα | Etanercept | Dimeric fusion protein | Not recommended for treatment of JIA-U | RCT: no more effective than placebo. Case reports of new uveitis on etanercept | |
Infliximab | Chimeric (mouse-human) mAb | 6 mg/kg IV initially, then 3–10 mg/kg. 2nd dose at 2 weeks, then every 4–8 weeks depending on response | Several case series showing efficacy | [61] | |
Adalimumab | Fully human mAb | 24Â mg/m2 sc q2w | Several case series showing efficacy. RCTs in progress | ||
In practice often 20 mg sc q2w (body weight <30 kg), 40 mg sc q2w (body weight ≥30 kg) | |||||
Golimumab | Fully human mAb | 50 mg sc q4w | Case series (n = 3) showing efficacy | [103] | |
IL-6 | Tocilizumab | Humanised mAb | 10 mg/kg (body weight <30 kg), 8 mg/kg (body weight >30 kg) IV q4w | Case series (n = 3) and case report showing efficacy. Phase II trial in progress | |
CD80/86 (CTLA4) | Abatacept | Fully human fusion protein | 10 mg/kg IV at weeks 0, 2, 4 then q4w | Case series (n = 7 and n = 2) showing efficacy. Lack of sustained response in severe uveitis (n = 21) | |
CD20 | Rituximab | Chimeric (mouse-human) mAb | 375 mg/m2 or 750 mg/m2 IV, two doses 2 weeks apart | Case series (n = 10 and n = 8 with long-term follow-up) showing efficacy in most patients |